A population pharmacokinetic trial to study patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease.
Phase of Trial: Phase IV
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- 09 Dec 2015 New trial record